 |
|
|
|
|
|
 |
|
|
|
| Sanofi-aventis Announces Final Results of Zentiva Offer |
| Sanofi-aventis, 19.05.2009 |
|
| Sanofi-aventis holds about 96.8% of share capital
13 Mar 2009 - Sanofi-aventis announced that following settlement of its voluntary public offer for Zentiva N.V., sanofi-aventis Europe now holds about 96.8% of Zentiva N.V.’s share capital. Over 27.7 million shares, including approximately three hundred twenty thousand in the form of GDSs, were purchased in the offer, and additional shares have been acquired following the end of the offer validity period.
Sanofi-aventis Europe’s shareholding in Zentiva N.V. satisfies the statutory 95% threshold for a squeezeout procedure of remaining minority shareholders in accordance with the applicable provisions of Dutch law. Sanofi-aventis intends to initiate such a procedure in the near future.
"I am personally very pleased to announce the successful outcome of our offer to acquire Zentiva and I am looking forward to welcoming the Zentiva employees into the sanofi-aventis group. Zentiva brings a large portfolio of branded generic drugs and affordable medicines, which is well adapted to market dynamics and patients needs in this region”, said Chris Viehbacher, CEO of sanofi-aventis.
odkaz na stránku |
|
|
|
|
|
|
|
|
|
|
|
|
Address : Euro-Brew Ltd., Hlboká 22, 917 01 Trnava, Slovakia
Tel. : +421 33 53 418 53, Fax : +421 33 53 418 52, E-mail : info@eurobrew.sk |
|
|
